Limits...
Astrocytoma

Lindsey DRL - MedPix (2010)

View Article: MedPix Image - MedPix Topic

Affiliation: Uniformed Services University

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

Gliomas account for nearly 80% of primary malignant brain tumors with a slightly higher incidence in men (male-to-female ratio of 1.5:1).2,8 Astrocytic tumors account for ? of all gliomas and glioblastomas (glioblastoma multiforme or GM), a World Health Organization (WHO) grade IV astrocytoma, is the most common type of glioma in adults.1,3,5 Pilocytic astrocytomas (WHO grade I) are the most common gliomas in children with an incidence of 0.37 per 100,000... Pilocytic astrocytomas are slow growing and account for 21-23% of all pediatric brain tumors... Conversely, studies have shown that those with asthma and allergies/high levels of serum IgE may have a decreased risk for glioblastoma.1,2,8 In addition, use of anti-inflammatory drugs have been linked to decreased risk of glioma.2 Examples of inherited genetic syndromes known to increase risk of brain tumors include Li-Fraumeni syndrome, neruofibromatosis 1 and 2, tuberous sclerosis, retinoblastoma and Turcot’s syndrome.1,2,6 However, only a very small percentage of gliomas are attributed to these risk factors... Interestingly, there is evidence for familial aggregation of gliomas in families that do not have the inherited genetic syndromes mentioned above... Current research is being conducted to identify genes associated with gliomagenesis.6 Seizures are only seen in 15%-30% of patients with malignant gliomas.11 Diagnosis of malignant astrocytomas includes MRI with contrast imaging... Survival and response to treatment is multifactorial... In addition to age at diagnosis and WHO grade, the extent of tumor resection, tumor location, radiation/chemotherapy protocols, and Karnofsky performance at diagnosis are all related to prognosis... Younger age at diagnosis (with the exception of infants), lower grade, greater extent of tumor resection, and high Karnofsky performance scores at diagnosis are all associated with a better prognosis.2,3,7,8 In addition, DNA repair enzyme methylguanine methyltransferase (MGMT) inactivation via methylation may be associated with improved outcome in glioblastoma patients who receive temozolomide whereas EGFR amplification may be associated with decreased survival in ages 55-60.2,9 Temozolomide has increased the median survival to 12-14 months.2 Those who are older and those with a tumor of a higher WHO grade have the worst prognosis... Glioblastomas have an overall 5 year survival rate of 3.3% with only 2% of patients aged 65 years or older and 30% of those under 45 years old at glioblastoma diagnosis surviving for 2 years or more.

No MeSH data available.


Seen at low power magnification is the high cellularity typical of an anaplastic astrocytoma (Grade III astrocytoma). The high power view shows two additional diagnostic features of this neoplasm: marked nuclear atypia and mitotic figures. Necrosis is absent.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=MPX2749&req=5

MPX2749_synpic48162: Seen at low power magnification is the high cellularity typical of an anaplastic astrocytoma (Grade III astrocytoma). The high power view shows two additional diagnostic features of this neoplasm: marked nuclear atypia and mitotic figures. Necrosis is absent.


Astrocytoma

Lindsey DRL - MedPix (2010)

Seen at low power magnification is the high cellularity typical of an anaplastic astrocytoma (Grade III astrocytoma). The high power view shows two additional diagnostic features of this neoplasm: marked nuclear atypia and mitotic figures. Necrosis is absent.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=MPX2749&req=5

MPX2749_synpic48162: Seen at low power magnification is the high cellularity typical of an anaplastic astrocytoma (Grade III astrocytoma). The high power view shows two additional diagnostic features of this neoplasm: marked nuclear atypia and mitotic figures. Necrosis is absent.

View Article: MedPix Image - MedPix Topic

Affiliation: Uniformed Services University

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

Gliomas account for nearly 80% of primary malignant brain tumors with a slightly higher incidence in men (male-to-female ratio of 1.5:1).2,8 Astrocytic tumors account for ? of all gliomas and glioblastomas (glioblastoma multiforme or GM), a World Health Organization (WHO) grade IV astrocytoma, is the most common type of glioma in adults.1,3,5 Pilocytic astrocytomas (WHO grade I) are the most common gliomas in children with an incidence of 0.37 per 100,000... Pilocytic astrocytomas are slow growing and account for 21-23% of all pediatric brain tumors... Conversely, studies have shown that those with asthma and allergies/high levels of serum IgE may have a decreased risk for glioblastoma.1,2,8 In addition, use of anti-inflammatory drugs have been linked to decreased risk of glioma.2 Examples of inherited genetic syndromes known to increase risk of brain tumors include Li-Fraumeni syndrome, neruofibromatosis 1 and 2, tuberous sclerosis, retinoblastoma and Turcot’s syndrome.1,2,6 However, only a very small percentage of gliomas are attributed to these risk factors... Interestingly, there is evidence for familial aggregation of gliomas in families that do not have the inherited genetic syndromes mentioned above... Current research is being conducted to identify genes associated with gliomagenesis.6 Seizures are only seen in 15%-30% of patients with malignant gliomas.11 Diagnosis of malignant astrocytomas includes MRI with contrast imaging... Survival and response to treatment is multifactorial... In addition to age at diagnosis and WHO grade, the extent of tumor resection, tumor location, radiation/chemotherapy protocols, and Karnofsky performance at diagnosis are all related to prognosis... Younger age at diagnosis (with the exception of infants), lower grade, greater extent of tumor resection, and high Karnofsky performance scores at diagnosis are all associated with a better prognosis.2,3,7,8 In addition, DNA repair enzyme methylguanine methyltransferase (MGMT) inactivation via methylation may be associated with improved outcome in glioblastoma patients who receive temozolomide whereas EGFR amplification may be associated with decreased survival in ages 55-60.2,9 Temozolomide has increased the median survival to 12-14 months.2 Those who are older and those with a tumor of a higher WHO grade have the worst prognosis... Glioblastomas have an overall 5 year survival rate of 3.3% with only 2% of patients aged 65 years or older and 30% of those under 45 years old at glioblastoma diagnosis surviving for 2 years or more.

No MeSH data available.